logo-loader

Humanigen achieves significant milestone in dosing first coronavirus patient in Phase 3 trial

Published: 10:54 11 May 2020 EDT

Humanigen Inc (OTCQB:HGEN) CEO Cameron Durrant tells Proactive its first coronavirus patient has been dosed in a Phase 3 trial of its drug lenzilumab.

Durrant says the now ongoing trial is the first randomized, double-blind, placebo-controlled, multi-center, Phase 3 study of an anti-GM-CSF conducted in the US.

Poseidon Nickel signs binding agreement with Mineral Resources to divest...

Departing Poseidon Nickel Ltd (ASX:POS, OTC:PSDNF) CEO Craig Jones and incoming CEO Brendan Shalders join Proactive’s Jonathan Jackson to discuss the divestment of Lake Johnston to Mineral Resources Ltd (ASX:MIN). Jones, who has played a pivotal role in this strategic move, shared insights on...

5 hours, 52 minutes ago